Publications

5600 Results

Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial

Authors
J Ligibel;K Ballman;L McCall;P Goodwin;A Weiss;T Crane;M Irwin;C Thomson;O Hahn;P Spears;D Hershman;E Paskett;J Hopkins;V Bernstein;V Stearns;J White;T Wadden;E Winer;L Carey;A Partridge
Journal / Conference
ESMO (September 13-17, 2024, Barcelona, Spain), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011401

Beyond Involved-Site Radiotherapy: NRG, COG, ALLIANCE, ECOG, SWOG, and CCTG Consensus Nomenclature for Radiation Targets on NCTN Lymphoma Trials

Authors
O Saifi;C Pinnix;L Ballas;C Kelsey;S Milgrom;S Terezakis;N Figura;R Parikh;J Grecula;J Plastaras;D Hodgson;B Hoppe
Journal / Conference
ASTRO Annual Meeting (September 29 - October 2, 2024, Washington, DC), Quick Pitch Oral Presention; International Journal of Radiation Oncology, Biology, Physics Volume 120:Number 2S
Year
2024
Research Committee(s)
Lymphoma

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vulvar Cancers

Authors
Y Chae;L Corthell;S Patel;R Edwards;J Scalici;H Kim;L Il-Young Chung;M Othus;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Nov 19. doi: 10.1158/1078-0432.CCR-24-1957. Online ahead of print
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39561273
Study Number(s)
S1609

Evaluation of a prognostic scoring system among patients in the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction Study (SWOG 1316)

Authors
C Watson;K Arnold;R Krouse;G Anderson;J Deneve;G Deutsch;B Davidson;A Secord
Journal / Conference
IGCS Meeting (October 16-18, 2024 Dublin, Ire), poster
Year
2024
Research Committee(s)
Palliative Care
Study Number(s)
S1316

Correlation of body mass index with overall survival in patients with metastatic hormone-sensitive prostate cancer: Analysis of patient-level data from SWOG-1216 study

Authors
U Swami;Y Jo;A Narang;M Plets;C Chehade;G Gebrael;S Gupta;Z Myint;C Tangen;P Lara;I Thompson;M Hussain;T Dorff;S Lerner;N Agarwal
Journal / Conference
European Urology Oncology Nov 8:S2588-9311(24)00241-4
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID39521639
Study Number(s)
S1216

Utilization of genomic tumor testing (GTT) among community oncologists participating in SWOG S2108CD

Authors
M Trivedi;A Michel;J Unger;S Colby;L Graham;K Reed;J Fischer;B Symington;S Ramsey;D Hershman;J Rueter
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster;JCO Oncol Pract 20, 2024 (suppl 10; abstr 320)
Year
2024
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S2108CD

The Cost of Doing Business – Drug Costs in Federally-Sponsored Cancer Clinical Trials

Authors
J Unger;H Xiao;R Vaidya;S Threlkel;M Chansky;A Hayes;D Hershman;M LeBlanc
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster; JCO Oncol Pract 20, 2024 (suppl 10; abstr 10)
Year
2024
Research Committee(s)
Cancer Care Delivery

Correlations Between Baseline Tumor Burden and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
P Swiecicki;M Othus;S Patel;Y Chae;R Kurzrock
Journal / Conference
SITC (Nov. 6-10, Houston, TX), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

Authors
S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;S Parsons;F Keller;R Drachtman;A Lambert;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;R Little;M Smith;H Dillon;J Song;S Smith;J Friedberg;K Kelly
Journal / Conference
ISHL (October 26-28, Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients (aged =60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826

Authors
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens
Journal / Conference
ISHL (October 26-28, Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826